Nonsteroidal Antiinflammatory Drugs — Differences and Similarities

New England Journal of Medicine

Volumn 324, Issue 24, 1991, Pages 1716-1725

  Brooks, Peter M ^a   Day, Richard O ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AZAPROPAZONE; DICLOFENAC; DIFLUNISAL; DIURETIC AGENT; ETODOLAC; FENBUFEN; FENOPROFEN; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; PIRPROFEN; SALICYLIC ACID; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLMETIN;

ADVERSE DRUG REACTION; CLASSIFICATION; DRUG COMPARISON; DRUG EFFECT; DRUG INTERACTION; DRUG MECHANISM; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0025856636     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199106133242407     Document Type: Review

References (110)

1. Clive D.M., Stoff J.S. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310:563-572
2. Langman M.J.S. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 1988; 84:Suppl 2A:15-19
3. Hall R.C. Patterns in drug utilization — national and international aspects: drug use in Australia. Acta Med Scand Suppl 1984; 683:79-80.
4. Roth S.H. Salicylates revisited: are they still the hallmark of anti-inflammatory therapy? Drugs 1988; 36:1-6.
5. Pincus T., Callahan L.F. Clinical use of multiple nonsteroidal anti-inflammatory drug preparations within individual rheumatology private practices. J Rheumatol 1989; 16:1253-1258
6. Dukes M.N.G., Lunde I. The regulatory control of non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1981; 19:3-10.
7. Netter P., Lapicque F., Bannwarth B., Tamisier J.N., Thomas P., Royer R.J. Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur J Clin Pharmacol 1985; 29:319-321
8. Goodwin J.S., Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25:1013-1015
9. Brune K., Graft P. Non-steroid anti-inflammatory drugs: influence of extracellular pH on biodistribution and pharmacological effects. Biochem Pharmacol 1978; 27:525-530
10. Cummings N.A., Nordby G.L. Measurement of synovial fluid pH in normal and arthritic knees. Arthritis Rheum 1966; 9:47-56.
11. Ciabattoni G., Boss A.H., Patrignani P., et al. Effects of sulindac on renal and extrarenal eicosanoid synthesis. Clin Pharmacol Ther 1987; 41:380-383
12. Ciabattoni G., Cinotti G.A., Pierucci A., et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease: evidence for the dependence of renal function on prostacyclin. N Engl J Med 1984; 310:279-283
13. Roberts D.G., Gerber J.G., Barnes J.S., Zerbe G.O., Nies A.S. Sulindac is not renal sparing in man. Clin Pharmacol Ther 1985; 38:258-265
14. Quintero E., Gines P., Arroyo V., et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986; 42:298-303.
15. del Favero A. Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout. In: Dukes MNG, Beeley L, eds. Side effects of drugs annual 11. Amsterdam: Elsevier, 1987: 82-106.
16. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature [New Biol] 1971; 231:232-235
17. Higgs G.A., Moncada S., Vane J.R. The mode of action of anti-inflammatory drugs which prevent peroxidation of arachidonic acid. Clin Rheum Dis 1980; 6:675-693
18. Lands W.E.M., Hanel A.M. Inhibitors and activators of prostaglandin biosynthesis. In: Pace-Asciak C, Granstrom E, eds. Prostaglandins and related substances. Amsterdam: Elsevier Science, 1983: 203-23.
19. Abramson S.B., Weissman G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32:1-9.
20. Forrest M., Brooks P.M. Mechanism of action of non-steroidal anti-rheumatic drugs. Clin Rheumatol 1988; 2:275-294
21. Preston S.J., Arnold M.H., Beller E.M., Brooks P.M., Buchanan W.W. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis. Br J Clin Pharmacol 1989; 27:607-611
22. Bray M.A. Leukotrienes in inflammation. Agents Actions 1986; 19:87-99.
23. Kitchen E.A., Dawson W., Rainsford K.D., Cawston T. Inflammation and possible modes of action of anti-inflammatory drugs. In: Rainsford KD, ed. Anti-inflammatory and anti-rheumatic drugs. Vol. 1. Inflammation mechanisms and actions of traditional drugs. Boca Raton, Fla.: CRC Press, 1985: 21-87.
24. Seigel M.I., McConnell R.T., Cuatrecasas P. Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14–eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci U S A 1979; 76:3774-3778
25. Ku E.C., Lee W., Kothari H.V., Scholer D.W. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986; 80:Suppl 4B:18-23.
26. O#x0027;Neill L.A.J., Lewis G.P. Inhibitory effects of diclofenac and indomethacin on interleukin-1-induced changes in PGE2 release. Biochem Pharmacol 1989; 38:3707-3711
27. Biemond P., Swaak A.J., Penders J.M., Beindroff C.M., Koster J.F. Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by antirheumatic drug piroxicam due to interference with activation of the NADPH-oxidase. Ann Rheum Dis 1986; 45:249-255
28. Bomalaski J.S., Hirata F., Clark M.A. Aspirin inhibits phospholipase C. Biochem Biophys Res Commun 1986; 139:115-121
29. Minta J.O., Williams M.D. Some nonsteroidal antiinflammatory drugs inhibit the generation of Superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J Rheumatol 1985; 12:751-757
30. Abramson S., Korchak H.M., Ludewig R., et al. Modes of action of aspirin-like drugs. Proc Natl Acad Sci U S A 1985; 82:7227-7231
31. Herman J.H., Appel A.M., Khosla R.C., Kelch K.S., Hess E.V. Cytokine modulation of chondrocyte metabolism: in vivo and in vitro effects of piroxicam. Inflammation 1984; 8:Suppl:S125-S137.
32. Ceuppens J.L., Rodriguez M.A., Goodwin J.S. Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet 1982; 1:528-530
33. Cush J.J., Lipsky P.E., Postlethwaite A.E., Schrohenloher R.E., Saway A., Koopman W.J. Correlation of serological indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990; 33:19-28.
34. Day R.O., Furst D.E., Dromgoole S.H., Kamm B., Roe R., Paulus H.E. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther 1982; 31:733-740
35. Luftschein S., Bienenstock H., Varady J.C., Stitt F.W. Increasing dose of naproxen in rheumatoid arthritis: use with and without corticosteroids. J Rheumatol 1979; 6:397-404.
36. Dunagan F.M., McGill P.E., Kelman A.W., Whiting B. Naproxen dose and concentration:response relationship in rheumatoid arthritis. Br J Rheumatol 1988; 27:48-53.
37. Furst D.E., Caldwell J.R., Klugman M.P., et al. Serum concentration and dose–response relationships for carprofen in rheumatoid arthritis. Clin Pharmacol Ther 1988; 44:186-194
38. Grennan D.M., Aarons L., Siddiqui M., Richards M., Thompson R., Higham C. Dose–response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol 1983; 18:311-316
39. Orme M.L. The relationship between plasma concentration of non-steroidal anti-inflammatory drugs and their therapeutic effects. Agents Actions Suppl 1988; 17:151-155
40. Day R.O., Graham G.G., Bieri D., et al. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 1989; 28:695-702.
41. Carson J.L., Strom B.L., Morse M.L., et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147:1054-1059
42. Baber N., Halliday L.D.C., van den Heuval W.J.A., et al. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders. Ann Rheum Dis 1979; 38:128-136
43. Capell H.A., Konetschnik B., Glass R.C. Anti-inflammatory analgesic responders and nonresponders: a clinico-pharmacological study of flurbiprofen. Br J Clin Pharmacol 1977; 4:623-624
44. Day R.O., Graham G.G., Williams K.M., Champion G., de Jager J. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1987; 33:384-433.
45. Kowanko I.C., Pownall R., Knapp M.S., Swannell A.J., Maloney P.G.C. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol 1981; 11:477-484
46. Levi F., Le Louarn C., Reinberg A. Timing optimizes sustained-release indomethacin treatment of osteoarthritis. Clin Pharmacol Ther 1985; 37:77-84.
47. Day R.O., Graham G.G., Williams K.M. Pharmacokinetics of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988; 2:363-393
48. Day R.O., Williams K.M., Graham G.G., Lee E.J., Knihinicki R.D., Champion G.D. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 1988; 43:480-487
49. Christophidis N., Rotstein A., Louis W.J. Acute and chronic pharmacokinetic studies of slow-release ketoprofen (Oruvail) in rheumatoid arthritis. Clin Exp Pharmacol Physiol 1986; 13:555-561
50. Van den Ouweland F.A., Gribnau F.W.J., Van Ginneken C.A.M., Tan Y., Van de Putte L.B.A. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clin Pharmacol Ther 1988; 43:79-85.
51. Upton R.A., Williams R.L., Kelly J., Jones R.M. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984; 18:207-214
52. Lee E.J.D., Williams K., Day R., Graham G., Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19:669-674
53. Williams K.M., Day R.O., Knihinicki R.D., Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986; 35:3403-3405
54. Schneider H.T., Nuernberg B., Dietzel K., Brune K. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br J Clin Pharmacol 1990; 29:127-131
55. Meffin P.J. The effect of renal dysfunction on the disposition of non-steroidal anti-inflammatory drugs forming acyl-glucuronides. Agents Actions Suppl 1985; 17:85-89
56. Dunn M.J., Patrono C., eds. Renal effects of nonsteroidal anti-inflammatory drugs. Am J Med 1986; 81:Suppl 2B:1-132.
57. Day R.O. Variability in response to NSAID. Agents Actions Suppl 1985; 17:15-19
58. Gøtzsche P.C. Methodology and overt and hidden bias in reports of 196 double blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials 1989; 10:31-56.
59. Erratum, Controlled Clin Trials 1989; 10:356.
60. Huskisson E.C., Woolf D.L., Balme H.W., Scott J., Franklyn S. Four new anti-inflammatory drugs: responses and variations. BMJ 1976; 1: 1048-9.
61. Orme M., Baber N., Keenan J., Halliday L., Sibeon R., Littler T. Pharmacokinetics and biochemical effects in responders and non-responders to nonsteroidal anti-inflammatory drugs. Scand J Rheumatol Suppl 1981; 39:19-27.
62. Gall E.P., Caperton J.F., McComb J.E., et al. Clinical comparison of ibuprofen, fenoprofen calcium, naproxen and tolmentin sodium in rheumatoid arthritis. J Rheumatol 1982; 9:402-407
63. Scott D.L., Roden S., Marshall T., Kendall M.J. Variations in response to non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1982; 14: 691-4.
64. Wasner C., Britton M.C., Kraines G., Kaye R.L., Bobrove A.N., Fries J.F. Non–steroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981; 246:2168-2172
65. Capell H.A., Rennie J.A.N., Rooney P.J., et al. Patient compliance: a novel method of testing non-steroidal antiinflammatory analgesics in rheumatoid arthritis. J Rheumatol 1979; 6:584-593
66. Luggen M.E., Gartside P.S., Hess E.V. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. J Rheumatol 1989; 16:1565-1569
67. Preston S.J., Arnold M.H., Beller E.M., Brooks P.M., Buchanan W.W. Variability in response to nonsteroidal anti-inflammatory analgesics: evidence from controlled clinical therapeutic trial of flurbiprofen in rheumatoid arthritis. Br J Clin Pharmacol 1988; 26:759-764
68. Day R.O., Graham G.G., Williams K.M., Brooks P.M. Variability in response to NSAIDs: fact or fiction? Drugs 1988; 36:643-651
69. Gottlieb N.L. The art and science of non-steroidal anti-inflammatory drug selection. Semin Arthritis Rheum 1985; 15:Suppl 2:1-3.
70. Wilske K.R., Healey L.A. Remodelling the pyramid — a concept whose time has come. J Rheumatol 1989; 15:565-567
71. Seideman P., Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 1988; 27:117-122
72. Heller C.A., Ingelfinger J.A., Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin — analysing the scores. Pharmacotherapy 1985; 5: 30-38.
73. Doyle D.V., Dieppe P.A., Scott J., Huskisson E.C. An articular index for the assessment of osteoarthritis. Ann Rheum Dis 1981; 40:75-78
74. Parr G., Darekar B., Fletcher A., Bulpitt C.J. Joint pain and quality of life: results of a randomised trial. Br J Clin Pharmacol 1989; 27:235-242
75. Ghosh P. Anti-rheumatic drugs and cartilage. Baillieres Clin Rheumatol 1988; 2:309-338
76. Doherty M., Holt M., MacMillan P., Watt I., Dieppe P.A. A reappraisal of #x0027;analgesic hip.#x0027; Ann Rheum Dis 1986; 45:272-276
77. Pelletier J.P., Martel-Pelletier J. The therapeutic effects of NSAID and corticosteroids in osteoarthritis: to be or not to be. J Rheumatol 1989; 16:266-269
78. Rashad S., Revell P., Hemingway A., Low F., Rainsford K., Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 2:519-522
79. Champion G.D. Therapeutic usage of the non-steroidal anti-inflammatory drugs. Med J Aust 1988; 149:203-213
80. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions — 1. BMJ 1986; 292:614
81. O#x0027;Brien W.M., Bagby G.F. Rare adverse reactions to nonsteroidal anti-inflammatory drugs. J Rheumatol 1985; 12:13-20, 347-53, 562–7, 785–90.
82. Brooks P.M. Side effects of non-steroidal anti-inflammatory drugs. Med J Aust 1988; 148:248-251
83. Henry D.A. Side effects of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988; 2:425-454
84. Bjarnason I., Zanelli G., Prowse P., et al. Blood and protein loss via small intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; 2:711-714
85. Langman M.J.S. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 1989; 96:Suppl 2:640-646
86. Fries J.F., Miller S.R., Spitz P.W., Williams C.A., Hubert H.B., Bloch D.A. Towards an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96:Suppl 2:647-655
87. Carson J.L., Strom B.L., Soper K.A., et al. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987; 147:85-88
88. Beard K., Walker A.M., Perera D.R., Jick H. Nonsteroidal anti-inflammatory drugs and hospitalisation for gastroesophageal bleeding in the elderly. Arch Intern Med 1987; 147:1621-1623
89. Somerville K., Faulkner G., Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1:462-464
90. Guess H.A., West R., Strand L.M., et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol 1988; 41:35-45.
91. Hawkey C.J. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990; 300:278-284
92. Soll A.H. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322:909-916
93. Langman M.J.S. Treating ulcers in patients receiving anti-arthritic drugs. Q J Med 1989; 73:1089-1091
94. Walan A., Bader J.-P., Classen M., et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69-75.
95. Roth S., Agrawal N., Mahowald M., et al. Misopostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149:775-779
96. Graham D.Y., Agrawal N., Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2:1277-1280
97. Edelson J.T., Tosteson A.N.A., Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264:41-47
98. Lifschitz M.D. Prostaglandins and renal blood flow: in vivo studies. Kidney Int 1981; 19:781-785
99. Schnermann J., Briggs J.P. Participation of renal cortical prostaglandins in the regulation of glomerular filtration rate. Kidney Int 1981; 19:802-815
100. Kokko J.P. Effects of prostaglandins on renal epithelial electrolyte transport. Kidney Int 1981; 19:791-796
101. Henrich W.L. Role of prostaglandins in renin secretion. Kidney Int 1981; 19:822-830
102. Whelton A., Stout R.L., Spilman P.S., Klassen D.K. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990; 112:568-576
103. Murray M.D., Brater D.C. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 1990; 112:559-560
104. Garella S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine (Baltimore) 1984; 64:165-181
105. Swartz S.L., Williams G.R. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol 1982; 49:1405-1409
106. Davis A., Day R.O., Begg E.J. Interactions between non-steroidal anti-inflammatory drugs and antihypertensives and diuretics. Aust N Z J Med 1986; 16:537-546
107. Favre L., Glasson P.H., Riondel A., Vallotton M.B. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci 1983; 64:407-415
108. Radack K., Deck C. Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients? J Gen Intern Med 1987; 2:108-112
109. Tonkin A.L., Wing L.M.H. Interactions of non-steroidal antiinflammatory drugs. Baillieres Clin Rheumatol 1988; 2:455-483
110. O#x0027;Reilly R.A., Trager W.F., Motley C.H., Howald W. Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest 1980; 65:746-753